glp-1 and gip receptors receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal GIP and GLP‐1, the two

According to King Law: The lawsuits primarily allege that manufacturers like Novo Nordisk (maker of Wegovy) failed to adequately warn patients and healthcare providers about the risks associated with these drugs, such as severe gastrointestinal complications like gastroparesis (stomach paralysis), ileus (intestinal obstruction), and recently, vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION). Prediction 2: More Emergency Room Visits Due to Adverse Effects In April 2025, Annals of Medicine reported that nearly 25,000 emergency room visits had occurred due to semaglutide adverse events in the years 2022 and 2023

Consideration GLP-1 (Semaglutide) GLP-1 + GIP (Tirzepatide) New to medical weight loss programs Want to target appetite regulation and digestion speed Need added support for insulin response & fat metabolism Have tried GLP-1 therapy before without desired results Prefer to start with one mechanism before adding a second Interested in dual-hormone approach for multiple pathways 2x weekly dosing and personalized guidance Which GLP weight loss program is right for you

Summary Moringa powder can be added to many drinks, taken as a capsule, or consumed as a tea

4